A trial to evaluate the effects of continuous treatment with denosumab in patients with rheumatoid arthritis (RA) and osteoporosis (OP)

Trial Profile

A trial to evaluate the effects of continuous treatment with denosumab in patients with rheumatoid arthritis (RA) and osteoporosis (OP)

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2016

At a glance

  • Drugs Denosumab (Primary)
  • Indications Osteoporosis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 May 2016 Primary endpoint (Changes from baseline at 12- and 24-month in BMD) has been met according to a results presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
    • 18 May 2016 New trial record
    • 17 Apr 2016 Results presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top